Chusri Sarunyou, Chongsuvivatwong Virasakdi, Rivera Jesabel I, Silpapojakul Kachornsakdi, Singkhamanan Kamonnut, McNeil Edward, Doi Yohei
Division of Infectious Disease, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Antimicrob Agents Chemother. 2014 Jul;58(7):4172-9. doi: 10.1128/AAC.02992-14. Epub 2014 May 12.
The role of Acinetobacter nosocomialis and Acinetobacter pittii, which belong to the A. calcoaceticus-A. baumannii complex, in hospital-acquired infections is increasingly recognized. Here we describe a retrospective cohort study of hospital-acquired A. calcoaceticus-A. baumannii complex infections at a university hospital in Thailand. A total of 222 unique cases were identified between January 2010 and December 2011. The genomospecies of the A. calcoaceticus-A. baumannii complex isolates were classified as follows: A. baumannii, 197 (89%); A. nosocomialis, 18 (8%); and A. pittii, 7 (3%). All A. nosocomialis and A. pittii isolates were susceptible to imipenem and meropenem. The patients infected with A. nosocomialis and A. pittii had lower 30-day mortality than those infected with carbapenem-susceptible A. baumannii (P = 0.025) and carbapenem-resistant A. baumannii (P = 0.013). The factors influencing 30-day mortality were infection with non-baumannii A. calcoaceticus-A. baumannii complex (hazard ratio [HR], 0.12; 95% confidence interval [CI], 0.03 to 0.51; P = 0.004), infection with carbapenem-resistant A. baumannii (HR, 1.57; 95% CI, 0.89 to 2.79; P = 0.105), appropriate empirical antimicrobial therapy (HR, 0.38; 95% CI, 0.23 to 0.61; P < 0.001), and higher acute physiology and chronic health evaluation II (APACHE II) score (HR, 1.15; 95% CI, 1.10 to 1.19; P < 0.001). In Galleria mellonella assays, the survival rates were significantly higher for the larvae infected with A. nosocomialis or A. pittii than for those infected with either carbapenem-susceptible A. baumannii or carbapenem-resistant A. baumannii, but no differences in survival rates were observed between carbapenem-susceptible A. baumannii and carbapenem-resistant A. baumannii. These findings suggest intrinsic differences in virulence between non-baumannii A. calcoaceticus-A. baumannii complex species and A. baumannii but not between carbapenem-susceptible and resistant A. baumannii.
隶属于醋酸钙不动杆菌-鲍曼不动杆菌复合体的医院感染不动杆菌和皮氏不动杆菌在医院获得性感染中的作用日益受到认可。在此,我们描述了泰国一家大学医院对医院获得性醋酸钙不动杆菌-鲍曼不动杆菌复合体感染的一项回顾性队列研究。2010年1月至2011年12月期间共确定了222例独特病例。醋酸钙不动杆菌-鲍曼不动杆菌复合体分离株的基因组种分类如下:鲍曼不动杆菌,197例(89%);医院感染不动杆菌,18例(8%);皮氏不动杆菌,7例(3%)。所有医院感染不动杆菌和皮氏不动杆菌分离株对亚胺培南和美罗培南敏感。感染医院感染不动杆菌和皮氏不动杆菌的患者30天死亡率低于感染碳青霉烯敏感鲍曼不动杆菌的患者(P = 0.025)和感染碳青霉烯耐药鲍曼不动杆菌的患者(P = 0.013)。影响30天死亡率的因素包括感染非鲍曼醋酸钙不动杆菌-鲍曼不动杆菌复合体(风险比[HR],0.12;95%置信区间[CI],0.03至0.51;P = 0.004)、感染碳青霉烯耐药鲍曼不动杆菌(HR,1.57;95% CI,0.89至2.79;P = 0.105)、适当的经验性抗菌治疗(HR,0.38;95% CI,0.23至0.61;P < 0.001)以及较高的急性生理学与慢性健康状况评分II(APACHE II)(HR,1.15;95% CI,1.10至1.19;P < 0.001)。在大蜡螟试验中,感染医院感染不动杆菌或皮氏不动杆菌的幼虫存活率显著高于感染碳青霉烯敏感鲍曼不动杆菌或碳青霉烯耐药鲍曼不动杆菌的幼虫,但碳青霉烯敏感鲍曼不动杆菌和碳青霉烯耐药鲍曼不动杆菌之间未观察到存活率差异。这些发现表明非鲍曼醋酸钙不动杆菌-鲍曼不动杆菌复合体物种与鲍曼不动杆菌在毒力上存在内在差异,但碳青霉烯敏感和耐药鲍曼不动杆菌之间不存在差异。